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A B S T R A C T
Background
Parkinson’s disease patients commonly suffer from speech and vocal problems including dysarthric speech, reduced loudness and loss of
articulation. These symptoms increase in frequency and intensity with progression of the disease). Speech and language therapy (SLT)
aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental aids.
Objectives
To compare the efficacy of speech and language therapy versus placebo or no intervention for speech and voice problems in patients
with Parkinson’s disease.
Search methods
Relevant trials were identified by electronic searches of numerous literature databases including MEDLINE, EMBASE, and CINAHL,
as well as handsearching of relevant conference abstracts and examination of reference lists in identified studies and other reviews. The
literature search included trials published prior to 11th April 2011.
Selection criteria
Only randomised controlled trials (RCT) of speech and language therapy versus placebo or no intervention were included.
Data collection and analysis
Data were abstracted independently by CH and CT and differences settled by discussion.
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Main results
Three randomised controlled trials with a total of 63 participants were found comparing SLT with placebo for speech disorders in
Parkinson’s disease. Data were available from 41 participants in two trials. Vocal loudness for reading a passage increased by 6.3 dB
(P = 0.0007) in one trial, and 11.0 dB (P = 0.0002) in another trial. An increase was also seen in both of these trials for monologue
speaking of 5.4 dB (P = 0.002) and 11.0 dB (P = 0.0002), respectively. It is likely that these areclinically significant improvements.
After six months, patients from the first trial were still showing a statistically significant increase of 4.5 dB (P = 0.0007) for reading and
3.5 dB for monologue speaking. Some measures of speech monotonicity and articulation were investigated; however, all these results
were non-significant.
Authors’ conclusions
Although improvements in speech impairments were noted in these studies, due to the small number of patients examined, method-
ological flaws, and the possibility of publication bias, there is insufficient evidence to conclusively support or refute the efficacy of SLT
for speech problems in Parkinson’s disease. A large well designed placebo-controlled RCT is needed to demonstrate SLT’s effectiveness
in Parkinson’s disease. The trial should conform to CONSORT guidelines. Outcome measures with particular relevance to patients
with Parkinson’s disease should be chosen and patients followed for at least six months to determine the duration of any improvement.
P L A I N L A N G U A G E S U M M A R Y
Speech and language therapy for speech problems in Parkinson’s disease
Many people with Parkinson’s disease suffer from disorders of speech. The most frequently reported speech problems are weak, hoarse,
nasal or monotonous voice, imprecise articulation, slow or fast speech, difficulty starting speech, impaired stress or rhythm, stuttering
and tremor. People with the condition also tend to give fewer non-verbal cues, such as facial expressions and hand gestures. These
disabilities tend to increase as the disease progresses and can lead to serious problems with communication.
This review compared the benefits of speech and language therapy versus placebo (sham therapy) or no treatment for speech disorders
in Parkinson’s disease. Relevant trials were identified by electronic searches of 16 medical literature databases, various registers of clinical
trials and an examination of the reference lists of identified studies and other reviews.
Only randomised controlled trials were included in this review. These were studies where two groups of patients were compared, one
group had speech and language therapy, the other did not receive any therapy intended to improve speech. The patients were assigned
to each of the groups in a random fashion so as to reduce the potential for bias.
Three trials with a total of 63 patients were found comparing speech and language therapy with an untreated group. The quality of the
methods used in these trials was variable, with all studies failing in at least one critical area. All three of the controlled trials reported
a positive effect of speech and language therapy for speech disorders in Parkinson’s disease. Many of the outcome measures examined
appeared to improve by a clinically significant amount after therapy. However, it should be noted that there were flaws in the methods
used in these studies and only a small number of patients with Parkinson’s disease were examined. This means that there is insufficient
evidence to absolutely prove or disprove the benefit of speech and language therapy for the treatment of speech disorders in Parkinson’s
disease patients, but lack of evidence does not mean lack of effect.
A large well designed placebo-controlled randomised trial is needed to assess the effectiveness of speech and language therapy for speech
disorders in Parkinson’s disease. Outcome measures with particular relevance to people with Parkinson’s disease should be chosen and
the patients followed for at least six months to determine the duration of any improvement.
B A C K G R O U N D
For definition of terms see Table 1. Glossary
Speech problems are common in Parkinson’s disease and increase
in frequency and intensity with progression of the disease (Streifler
2Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1984; Sapir 2001). Dysarthria is a collective name for a group
of speech disorders resulting from disturbances in muscular con-
trol of the speech mechanism due to damage of the central ner-
vous system. It designates problems in oral communication due
to paralysis, weakness or incoordination of the speech muscu-
lature (Darley 1969). Common characteristics of Parkinsonian
dysarthria are monotony of pitch and volume (dysprosody), re-
duced stress, imprecise articulation, variations in speed resulting
in both inappropriate silences and rushes of speech, and a breathy
hoarseness to the speech (hypophonia) reflecting the difficulty the
patient has in synchronising talking and breathing (Logemann
1978; Stewart 1995). Many of these features are attributed to hy-
pokinesia (paucity ofmovement) and rigiditywhich are considered
to be cardinal features of Parkinson’s disease (Mawdsley 1971).
Parkinson’s disease patients also suffer from cognitive impairment
which leads to difficulties in language selection, language under-
standing, coordination and dual tasks (talking andwalking) as well
as emotional intent and understanding. These issues do not come
under the umbrella of dysarthric speech but impact on the ability
of individuals to participate in spoken communication. As a result
it was decided that the title of this review should be changed from
‘dysarthria’ to include the full complexity of ‘speech problems in
Parkinson’s disease’.
Four approaches to speech therapy are available: behavioural treat-
ment techniques (drill, exercise), instrumental aids including pros-
thetic and augmentative devices, medication, and surgical proce-
dures. Pharmacotherapy and surgery have a limited role in the
management of specific motor impairments such as speech dis-
orders, particularly those that emerge during later stages of the
disease. It has been suggested that the behavioural treatment tech-
niques of speech and language therapy (SLT) may be more effec-
tive in improving the intelligibility of speech in Parkinson’s dis-
ease. Even then, “compensated intelligibility” rather than “normal
speech”may be considered themore limited goal of SLT (Rosenbek
1985).
A 2009 patient survey by Parkinson’s UK showed that only 34%
of patients with Parkinson’s disease in England reported receiving
SLT (Parkinson’s disease society 2008). This low referral rate does
not accord with the advice in most published guidelines which
suggests that SLT should always be made available for the man-
agement of Parkinson’s disease (NCC-CC 2006).
This review compared the efficacy of speech and language therapy
with placebo or no intervention for speech problems in patients
with Parkinson’s disease. Another review will examine trials that
compare two forms of SLT techniques.
O B J E C T I V E S
To compare the efficacy of speech and language therapy versus
placebo or no intervention for speech problems in patients with
Parkinson’s disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing speech and language
therapy with placebo or no intervention were considered for in-
clusion in the study. Both random and quasi-random methods of
allocation were allowed.
Types of participants
• Patients with a diagnosis of Parkinson’s disease (as defined
by the authors of the studies).
• Any duration of Parkinson’s disease.
• All ages.
• Any drug therapy.
• Any duration of treatment.
Types of interventions
Speech and language therapy, placebo or no intervention.
Types of outcome measures
1. Speech and voice production parameters (i.e. measures of im-
pairment):
(a) total impairments (dysarthria rating scale, intelligibility rating
scale);
(b) objective and subjective acoustic measures of speech samples
(pitch, loudness, sentence length etc.);
(c) measures of laryngeal activity (fibre optic laryngoscopy, stro-
boscopy);
(d) level of communication participation.
2. Activities of daily living (e.g. Sickness Impact Profile (SIP) com-
munication subsection).
3. Handicap and quality of life measures, both disease specific (e.g.
Parkinson’s Disease Questionnaire - 39, (PDQ39)) and generic
(e.g. Short Form - 36, (SF36)).
4. Depression rating scales (e.g. Beck Depression Index, (BDI)).
5. Adverse effects.
6. Carer outcomes (e.g. carer strain index).
7. Economic analysis.
We examined both short-term and long-term effects of the inter-
vention.
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Search methods for identification of studies
1. The review is based on the search strategy of the Cochrane
Movement Disorders Group and also the following more general
search strategy:
a. Dysarthria OR speech OR speak OR intelligibility OR dys-
prosody OR hypophonia OR monotonicity OR phonate
b. ((Speech OR speak OR language OR voice OR vocal OR ar-
ticulate OR sing) near (task OR therapy OR treatment OR train
OR counsel OR intervention OR exercise OR drill OR rehabili-
tation)) OR silverman OR LSVT
c. Parkinson OR Parkinson’s disease OR Parkinsonism
d. (#a AND #b AND #c) OR (#a and #c)
See Appendix 1 for sample search (MEDLINE). This strategy was
adapted for each electronic database.
Relevant trials were identified by electronic searches of general
biomedical and science databases: MEDLINE (1966 to 2011),
PubMed (2010 to 2011) EMBASE (1974 to 2011), CINAHL
(1982 to 2011), ISI-SCI ((1981 to 2011); rehabilitation databases:
AMED (1985 to 2011), MANTIS (1880 to 2000), REHAB-
DATA (1956 to 2011), REHADAT, GEROLIT (1979 to 2011);
English language databases of foreign language research and third
world publications: Pascal (1984 to 2000), LILACS (1982 to
2011), MedCarib (17th Century to 2000), Journal@rchive (19th
century to 2011), AIM (1993 to 2000), IMEMR (1984 to 2011)
and handsearching of appropriate conference proceedings. Rele-
vant trials were included on the Group’s specialised register of ran-
domised controlled trials.
2. The Cochrane Central Register of Controlled Trials (CEN-
TRAL), the CenterWatch Clinical Trials listing service, con-
trolled-trials.com, ClinicalTrials.gov, RePORT, PEDro, NIDRR
and NRR, were also searched for relevant trials.
3. The reference lists of located trials and review articles were
searched.
4. Grey literature (e.g. conference abstracts, theses and internal re-
ports)were searched.This includedThe InternationalCongress on
Parkinson’s disease (1999, 2001), The International Congress of
Parkinson’s Disease and Movement Disorders (1990, 1992, 1994,
1996 to 1998, 2002, 2004 to 2011), The American Academy of
Neurology 51st annual meeting (1999) and the Congress of the
European Federation of Neurological Societies (2003 to 2010).
The following grey literature databases were searched: Open-
SIGLE (1980 to 2011), ISI-ISTP (1982 to 2000), Proquest (1999
to 2011), Conference Papers Index (1982 to 2011) Ethos (1970
to 2011) and Index to Theses (1716 to 2011).
Further details on this search strategy are available in the Group’s
module within The Cochrane Library (www.cochrane.org). This
includes explanations of the acronyms, sources and websites.
Data collection and analysis
The review authors (CH, CT and CEC) independently assessed
the studies identified by the search strategy. Disagreements about
inclusions were resolved by discussion.
We contacted authors in the cases where further trial information
was required for full analysis. Full papers were assessed formethod-
ological quality by recording the method of randomisation and
blinding, whether an intention-to-treat analysis was used, if an a-
priori sample size calculation had been done, whether any selective
reporting was apparent, the credibility of the placebo used and the
similarity of the patients baseline characteristics as well as any loss
to follow up. In addition we assessed whether patients remained
on a stable drug regimen throughout the treatment period and
follow-up, and if not whether any changes were fully disclosed.
Two authors (CH and CT) abstracted data onto standardised
forms independently, checked them for accuracy and amalgamated
the results. Disagreements about inclusions were resolved by dis-
cussion.
We combined the results of each trial using standard meta-ana-
lytic methods (fixed-effect model) to estimate an overall effect for
speech and language therapy intervention versus no intervention.
All relevant outcomes were continuous variables: for these the
mean difference between treatment arms was calculated using
weightedmean differencemethods (Fleiss 1993). In summary, this
involved for each trial, calculating the mean change (and standard
deviation) from baseline to the post intervention time point for
both the intervention and no intervention groups. The mean dif-
ference and its variance between arms for each trial could then be
calculated. In some studies the standard deviation for the mean
change was not reported. In these cases we imputed this standard
deviation using the standard deviations for the baseline and final
scores. To do this we used the following formula to estimate the
variance of the change in score:
var diff = var pre + var post - 2r
√
(var pre var post )
where var diff is the variance of the change score; var pre is the
variance of the baseline score; var post is the variance of the final
score and r is the correlation between the pre- and post-treatment
scores. We assumed a correlation coefficient of 0.5, which is a
conservative estimate, to reduce the chance of false positive results
(Higgins 2011).
These values were then combined using weighted mean difference
methods to give the overall pooled estimate of themean difference,
with 95% confidence interval, for speech and language therapy
versus no therapy (control). A result with a value of P < 0.05 was
considered to be statistically significant.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
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See Table 2: Characteristics of Included Studies and Figure 1 for
PRISMA flow chart.
Three randomised controlled trials were found comparing speech
and language therapy with placebo for speech disorders in Parkin-
son’s disease. A total of 63 patients were examined.
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Figure 1. PRISMA flow diagram.
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TRIAL DESIGN
All trials were parallel group, single centre studies.
PARTICIPANTS
Johnson 1990’s and Ramig 2001’s baseline characteristics for both
treatment and placebo groups had a high degree of similarity be-
tween the groups. Robertson 1984 did not give the data on the
four withdrawals, all of whom were in the control group. There
was a difference of 10 years in the mean age of the two groups in
this study.
INTERVENTIONS
There were significant differences in the duration and intensity
of the therapy given to the patients. Johnson 1990 treated their
patients for 10 hours over four weeks, Ramig 2001 treated for 16
hours over four weeks and Robertson 1984 treated for 35 to 40
hours over two weeks. All studies were conducted in an outpatient
setting.
The methods of SLT differed in all of the trials. Johnson 1990
gave the patients individual therapy with the emphasis placed on
prosodic features of pitch and volume. Therapy was reinforced
with the use of a number of visual feedback systems. Robertson
1984 also aimed therapy at improving loudness and pitch varia-
tion but they also worked on respiration, voice production and
intelligibility. Like Johnson 1990, they used visual feedback to re-
inforce the therapy, however, most of this therapy was carried out
in a group setting with individual interventions carried out only
where needed. The therapy in Ramig 2001 aimed to maximize
phonatory effort and loudness during speech with improved vocal
fold adduction and overall laryngeal muscle activation and was
carried out on an individual basis. This method was referred to as
Lee Silverman Voice Therapy (LSVT).
CONTROL DESIGN
None of the three trials provided a description of the control inter-
vention. In personal communications with the authors of Ramig
2001 and Johnson 1990 they stated that their control group was
untreated. It is assumed that this was also the case in Robertson
1984 but we were unable to contact the authors to confirm this.
OUTCOME MEASURES
Robertson 1984 provided no raw data on any outcome measure,
and neither was this available from the authors. Ramig 2001 re-
ports the volume (synonymous to sound pressure level and loud-
ness - see Glossary Table 1) of various modes of speech as well as
measures of vowel articulation, including vowel formant frequen-
cies and perceptual ratings of vowel goodness. The sound pressure
level for reading a standard passage (the Rainbow passage) and for
a monologue was comparable with the volume measured for these
two activities in Johnson 1990’s study. Johnson 1990 also gave an
overall assessment of speech quality using the Frenchay Dysarthria
Assessment and of the pitch of the speech in the measure of fun-
damental frequency.
Ramig 2001 was the only study to carry out an extended follow-up
to determine the longevity of any improvements. Measurements
of volumewere repeated for all patients sixmonths after treatment.
EXCLUDED STUDIES
See Table: Characteristics of Excluded Studies.
We found twelve other trials and obtained the full papers to eval-
uate suitability of the trials for this review. Corte 2009 was a focus
group trial.Wang 2008 andWohlert 2004 did not adequately ran-
domise participants. Trials Evans 2006; Scott 1984 and Silverman
2006 had no control group while Quedas 2007 used a healthy
control group. Aguiar 2009 was a multidisciplinary trial with no
data available solely from SLT component and Katsikitis 1996 and
Patti 1996 concentrated on physiotherapeutic outcomes and did
not report and measures of speech. No information was available
for Cotter 2003 and Sapir 2007 was excluded due to incomplete
overlap with Ramig 2001.
Risk of bias in included studies
See Table 2 and Figure 2 for summary of the methodological
quality of the trials.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Blinding of patients and treating therapists in trials examining the
efficacy of SLT is not possible in practice. This leaves such trials
open to performance and attrition bias. Performance bias could be
due to factors such as the patients in the therapy group performing
better due to placebo and Hawthorn effects, whilst attrition bias
could be due to patients in the placebo group potentially being
more likely to withdraw from the trial due to disappointment at
not being placed in the active therapy arm. One study (Johnson
1990) used blinded raterswhich reduces the potential for detection
bias. Ramig 2001 offered treatment to everyone in the control
arm at the end of the follow-up period: this may have reduced the
potential for withdrawal from this arm of the trial.
RANDOMISATIONMETHODANDCONCEALMENTOF
ALLOCATION
Robertson 1984 used alternate allocation to randomise, which is
not a truly random method. Ramig 2001 used a ‘numbers pulled
out of a hat’ method of randomisation. Concealment of allocation
cannot be confirmed when using suchmethods, thus selection bias
cannot be excluded. Johnson 1990 did not state their method of
randomisation or concealment of allocation (see Glossary Table
1).
ELIGIBILITY CRITERIA
The eligibility criteria for the trials were broad. Johnson 1990
did not state any eligibility criteria although it is implicit in the
report that they only treated patients with Parkinson’s disease.
Ramig 2001 required that all individuals in their Parkinson’s dis-
ease groups had adequate hearing for daily communication and
were on a stable drug regime. Robertson 1984’s inclusion criteria
stated that the participants must have Parkinson’s disease and be
on a stable drug regime.
It is vital that eligibility criteria are well defined so that it is un-
derstood what sort of a population were treated. For example,
it is important that the Parkinson’s disease accords with the UK
Brain Bank Parkinson’s Disease criteria (Gibb 1988), otherwise
it is more likely that individuals with Parkinson’s plus syndromes
will be included which have a significantly different clinical course
compared to idiopathic Parkinson’s disease.
None of the trials stated explicitly that their patients had a speech
deficit. However, it is highly unlikely that individuals were referred
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for therapy unless they had some form of speech problem. Defin-
ing the severity of the speech problem would have enabled an as-
sessment of which patients benefit most from the therapy.
PARTICIPANT NUMBERS
A total of 63 patients were examined. With such a small number
of participants, it is unlikely that they were truly representative
of the Parkinsonian population as a whole. Overall only 18 of
the 63 patients examined were female (29%), which introduces
difficulties when trying to extrapolate the results of these trials to
the general Parkinson’s population.
SIMILARITY AT BASELINE
Considering the small number of patients in all of the studies, the
likelihood of an unequal distribution is high, as demonstrated by
the Robertson 1984 study where the two groups differed in their
mean age by 10 years. Differences like this suggest that themethod
of randomisation used was unsuitable.
The baseline characteristics of those patients who withdrew were
not given in Robertson 1984. Considering that the characteristics
of these four individuals may have contributed to their withdrawal
from the trial, it is important that this information should be
available.
Only Ramig 2001 gave an indication of the severity of Parkin-
son’s disease within the groups. This makes it difficult to judge
which patients would benefit most from the therapy and whether
the results are generalized across the international Parkinson’s dis-
ease population. It is accepted that the Hoehn and Yahr score as-
sesses physical disability and does not have a speech component;
however, it has been shown that impairment in speaking ability
increases in frequency and intensity with the progression of the
disease (Sapir 2001; Streifler 1984Sapir 2001).
DESCRIPTION OF SPEECH AND LANGUAGE THERAPY
The methods of speech and language therapy were broadly de-
scribed in the study publications. Ramig 2001 provided a refer-
ence to a book (Ramig 1995) that describes the LSVT method
in greater depth. Johnson 1990 provided a schedule of events for
each of the ten therapy sessions. Robertson 1984 provided a brief
description of the activities carried out during their therapy ses-
sions. It is important that sufficient detail is provided so that the
method of therapy can be repeated by other speech and language
therapists.
The drug therapy of the patients was constant in Ramig 2001
and Robertson 1984. Johnson 1990 stated that drug therapy was
constant for at least months prior to start of trial. It is important
that drug therapy is kept constant for the duration of the trial as
it has been shown that various drug therapies may affect speech
quality (Biary 1988; Dann 1994; Stewart 1995).
DESCRIPTION OF PLACEBO
None of the included studies used a placebo treatment. ’No ther-
apy’ is an inadequate control for the speech therapymethods being
studied as all the therapy groups were treated in an outpatients
department of a hospital and therefore had to get up in time for
their appointment, dress, travel, spend time in the company of
other patients etc. None of this is speech and language therapy
but it may have had an effect on the wellbeing and overall quality
of life (Hawthorne effect) of the patients with Parkinson’s disease
who took part.
DATA ANALYSIS
The data were analysed on a per protocol basis in Robertson 1984
(see Glossary Table 1), this means that the analysis of the data
could be biased if the drop-outs were due to the unacceptability
of the placebo (as all of the drop-outs were in the placebo arm).
There were four drop-outs in this study despite it only running for
two weeks. No baseline information was given for these patients.
It is assumed that Johnson 1990 and Ramig 2001 analysed their
data on an intention-to-treat basis (see Glossary Table 1) as there
were no withdrawals from these studies, though this was not stated
in the publications.
None of the studies statistically compared the change in a given
outcome measure (i.e. score after therapy minus score at baseline)
between the two groups (i.e. change due to therapy versus change
due to placebo). Robertson 1984 and Ramig 2001 statistically
compared the final scores between the two therapy groups. This
relies on the baseline characteristics of the two groups being very
similar, but with such small numbers of participants, variations
between the two groups at baseline are common. Johnson 1990
statistically compared the change in an outcome for each group
individually over time. This means that this trial does not examine
whether SLT is better than no treatment, only that changes, if any,
occurred after a given therapy.
OUTCOME MEASURES
An analysis of the clinimetric soundness of the outcome measures
used is included in the Discussion section of the review.
Effects of interventions
See Glossary: Table 1 and the Summary of Results Table: Table 3
A total of 63 individuals were randomised into the three trials
included in this review, no analysable data were available for the
22 patients from Robertson 1984, this meant that the number
available for numerical analysis was just 41. Both Ramig 2001
and Johnson 1990 compared mean values before and after the
treatment.We converted these to mean changes from baseline and
the mean differences between the groups were calculated along
with 95% confidence intervals (95 % CI) and significance values
(P).
SUMMARY ASSESSMENTS OF SPEECH IMPAIRMENT
Johnson 1990 measured total impairment with the Frenchay
Dysarthria Assessment, which improved significantly with therapy
by 29.0 points (95% CI 13.7 to 44.3; P = 0.0002) compared to
the no therapy group.
Robertson 1984 stated that the scores of the Dysarthria Profile
were comparable in the two groups at baseline. Immediately after
therapy the scores were significantly higher in the treatment group
compared to the placebo group (ANOVA: F(1,16) = 3.85, P <
0.05).
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SPEECH IMPAIRMENTS: LOUDNESS
See Glossary: Table 1 for explanations of the various terms used
to describe loudness.
Ramig 2001 measured loudness objectively (sound pressure level,
dB) with four different speaking modes, whilst Johnson 1990
studied two speaking modes (volume, dB). Both Ramig 2001 and
Johnson 1990 measured the mean loudness of a monologue. In
Ramig 2001 the patient chose the subject on which to talk, whilst
in Johnson 1990 the patients were given a list of subjects to se-
lect from. There was a statistically significant improvement in ob-
jective loudness of 11.0 dB (95% CI 3.98 to 18.02; P = 0.002)
in Johnson 1990 and 5.4 dB (95% CI 2.6 to 8.2; P = 0.0002)
in Ramig 2001 immediately after therapy. The results from these
studies are combined in a forest plot in Figure 3: although the
treatment methods were not the same in these two trials the plot
shows a significant improvement with therapy compared to no
therapy of 6.17 dB (95% CI 3.57 to 8.77; P < 0.00001). Ramig
2001 continued to follow their groups for six months at which
point the improvement in objective loudness had reduced to 3.5
dB (95% CI 0.9 to 6.1), but this was still a significant increase
(P = 0.009). When the patients were asked to describe a picture
in Ramig 2001 the mean objective loudness of speech was also
improved compared to baseline by 5.2 dB (95% CI 2.0 to 8.4;
P = 0.001) more in the LSVT group than the no therapy group
and this was maintained over six months (4.2 dB, 95% CI 1.1 to
7.3; P = 0.008). Ramig 2001 and Johnson 1990 both measured
the mean objective loudness of reading a standard passage both of
which improved by 6.3 dB (95% CI 3.5 to 9.1; P = 0.0007) and
11.0 dB (95% CI 5.2 to 16.9; P = 0.0002), respectively. These
results were also meta-analysed in a forest plot, shown in Figure 4,
the combined therapies gave an increase of 7.18 dB (95% CI 4.65
to 9.71; P = 0.00001) when compared with no therapy. Ramig
2001 again recorded reading loudness sixmonths after therapy and
showed that this improvement was mostly maintained (4.5 dB,
95% CI 1.9 to 7.1; P = 0.0007). Ramig 2001 also measured the
mean objective loudness of a prolonged ’ah’. Again this improved
after therapy by 12.1 dB (95% CI 8.9 to 15.4; P < 0.00001) and
the improvement was maintained for six months (9.4 dB, 95% CI
6.2 to 12.6; P < 0.00001).
Figure 3. Forest plot of comparison: 1 SLT Therapy versus no therapy, outcome: 1.1 SPL monologue
pre/post.
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Figure 4. Forest plot of comparison: 1 SLT therapy versus no SLT therapy, outcome: 1.2 SPL reading
pre/post.
SPEECH IMPAIRMENTS: MONOTONICITY
Johnson 1990 measured two variables that could influence the
monotonicity of speech and voice. Maximum pitch range was
found by asking the patients to sing up and down to their highest
and lowest notes. This improved by 66 Hz after therapy but the
change was not significant (95% CI -4.4 to 136.6; P = 0.07).
Maximum volume range was measured by asking the patients to
count to five starting with the quietest voice they could achieve
and ending with the loudest. There was a significant improvement
of 23.7 dB (95% CI 9.3 to 38.1; P = 0.001) after therapy for this
outcome.
SPEECH IMPAIRMENTS: PITCH
Johnson 1990 measured the mean pitch (fundamental frequency,
see Glossary Table 1) of saying ’ah’. There was a non-significant
difference of -65 Hz (95% CI -133 to 2; P = 0.06) between the
two groups, with approximately 30 Hz of this change attributable
to an increase in the placebo group.
OTHER OUTCOMES
No study provided any information on activities of daily living,
intelligibility of speech, quality of life, adverse events, carer out-
comes or performed an economic analysis.
D I S C U S S I O N
Summary of main results
1. Three randomised controlled trials were found comparing
speech and language therapy with placebo (63 participants);
numerical data were only available in two of the trials (41
participants). These trials varied significantly in their
methodology.
2. All of the trials claimed a positive effect of speech and
language therapy on speech problems in Parkinson’s disease.
Many of the outcome measures examined appeared to improve
by a clinically significant amount after therapy. However,
considering the small number of patients with Parkinson’s disease
examined, the methodological flaws in the studies, and the
possibility of publication bias, it is unsafe to draw firm
conclusions regarding the efficacy of speech and language
therapy.
3. Large well designed RCTs are needed to assess whether SLT
is effective in treating speech problems in Parkinson’s disease.
Overall completeness and applicability of
evidence
OUTCOME MEASURES
The outcome measures varied greatly between the trials. In two of
the three trials outcomemeasureswere only assessed at baseline and
immediately after therapy. It would have been valuable to know
the long-term duration of any improvement following therapy.
Summary assessments of speech impairment
The Frenchay Dysarthria assessment has been validated for use
with Parkinson’s disease patients. Personal communication with
the author of the scale has revealed that it is hard to determine
whether a 29 point gain in the summary score is clinically useful.
If the improvement was in areas associated with improvements in
’speech’ it would be seen as clinically useful, however, if gains were
in other parts of the test then they might not have a significant
impact on the patient’s communicative ability.
Speech impairments: loudness
Parkinsonian speech is often characterised by a quiet voice. This
can exacerbate problems with intelligibility as listeners strain to
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hear what is being said by the patient. The tests can be divided
into spontaneous and prompted speech. Spontaneous speech, such
as a monologue or describing a picture is harder for people with
Parkinson’s disease as it requires greater cognitive effort. However,
it is more ’real life’ than the prompted speech tests (reading or say-
ing ’ah’). It can be suggested that with current computer technol-
ogy it should be possible to record a conversation with a patient,
remove the therapists’ voice and then carry out vocal parameter
analysis (volume, pitch etc.) on the patient’s speech as it sounds in
their most common speaking activity.
The objective loudness (volume or sound pressure level measured
in decibels with a microphone) of the patients’ speech improved,
with all types of speech modality measured, after therapy. The
size of these improvements had reduced a little after six months.
When considering whether these improvements are clinically use-
ful it is helpful to examine Ramig 2001’s study. In addition to the
therapy and placebo groups of Parkinson’s disease patients, they
also examined 14 healthy, age matched people with no speech or
voice impairments. When the objective loudness of their speech
is compared to the total Parkinson’s disease group (therapy and
placebo combined) at baseline, averaged over all four of the out-
comes assessed, the healthy participants spoke 2.8 dB louder. All of
the improvements immediately after therapy in the patients with
Parkinson’s disease are at least twice as large as this, and even at six
months later all of the improvements in loudness are more than
3.5 dB. Therefore, this suggests that these increases in the loudness
of speech are useful to the participants. However, as the patients
and their carers were not asked whether they felt that their speech
had got louder and/or more intelligible, it cannot be said what
impact these improvements had on the patient’s communication
abilities.
Speech impairments: monotonicity
It is accepted that a patient’s maximum loudness and pitch varia-
tion will have an impact on the monotonicity of their day-to-day
conversation. It would have been more useful to measure the ob-
jective loudness and pitch variability in a sample of speech, how-
ever, it is recognised that at the time of the Johnson 1990 study
the technology may not have been easily available.
Speech impairments: pitch
The only measure of pitch of the patient’s speech was measured
by asking them to say ’ah’. This is a highly artificial situation, and
the standard deviations were quite large which may explain why
the pitch reduced in the therapy group, when therapy would have
been aimed at increasing pitch.
Activities of daily living (ADL)
It is important to assess the impact that poor communication
has on the ADL of patients with Parkinson’s disease. For exam-
ple, many patients have difficulty using a telephone or talking to
strangers. If after therapy they found that these skills improved,
this could also reduce their sense of isolation and so probably also
increase their quality of life.
Adverse Events
Adverse events were not reported by any of the trials included in
this review. Although the risk associated with speech and language
therapy is low, patients could be affected by vocal strain or abuse
during high effort exercises
Quality of life (QOL) and intelligibility
It is now generally accepted that quality of life measures should
be used as the primary outcome of interest in larger clinical trials
to provide a global patient-orientated perspective on an interven-
tion. However, with speech and language therapy it could be ar-
gued that the primary outcome of interest is improved intelligibil-
ity. At present quantifying this multi-factorial outcome is difficult
and there are few validated scoring systems that assess this out-
come. One available system is the Assessment of Intelligibility for
Dysarthric Speech (AIDS), which quantifies single-word intelligi-
bility, sentence intelligibility, and speaking rate. None of the trials
reviewed used QOL or intelligibility scales. Therefore, the trials
reported here cannot be used to inform sample size calculations
for future trials.
Depression
The effectiveness of the therapy could potentially be affected by
depression. Depressed patients could be less compliant both dur-
ing the therapy sessions and also in the practice at home. The
therapy itself might affect depression. The patient’s moodmay im-
prove due to the attention they are being paid by the therapist, by
getting out of the house andmeeting other people. Awell designed
placebo intervention would control for the non-therapeutic con-
founders. If the therapy affected the patient’s physical well-being
so that they felt more in control and able to carry out more of
their ADL independently, this could improve the patient’s mood.
Also it is important to measure depression, as a number of surveys
(GPDS 2000; Karlsen 1999; Visser 2008; Zach 2004) have found
depression to be the main contributor to reduction in quality of
life due to Parkinson’s disease.
Carer outcomes
Approximately 75%of Parkinson’s disease patients live with a part-
ner, who is usually of a similar age and may have disabilities of
their own (Lloyd 1999). The impact of caring for a person with
Parkinson’s can be severe (O’Reilly 1996), and it would be hoped
that an intervention such as speech and language therapy could
have a positive effect on the carer’s life as well as the patient’s. It is
also important to assess the carer’s perception of the speech impair-
ment as they are usually the ones that have the greatest interaction
with the person with Parkinson’s disease.
Health economics
No health economics analysis of speech and language therapy has
been performed, which precludes an understanding of the eco-
nomic value of this therapy. If we can prove that SLT works, we
then need to persuade health care purchasers to buy the service.
They need to know whether it is cost neutral or whether it in-
creases or decreases the overall costs of care and whether this is
balanced by improvements in efficacy.
SPEECH AND LANGUAGE THERAPY METHODOLOGY
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There is no consensus amongst therapists on which SLT method
to use or whether it should be a combination of methods. A recent
survey of speech and language therapists in the UK (Miller 2011a)
showed a high proportion of patients with Parkinson’s disease re-
ferred for SLT receive only an assessment, advice and review ser-
vice. When treatment methods were employed, voice quality was
most commonly addressed with LSVT or other vocal loudness ex-
ercises and intelligibility was treated with pacing/rate control ex-
ercises supported by work on loudness. Psychosocial and language
strategies were rarely employed by the therapists surveyed despite
these being flagged as important reasons for referral. Over 75%
of all therapists surveyed wanted further training and over half of
these specifically desired training in LSVT techniques. As part of
the same study a survey of SLT provision was carried out with pa-
tients with Parkinson’s disease and their carer’s (Miller 2011b). Of
the 83 patients who had received any treatment from a speech and
language therapist, 56% had their sessions in a local clinic or hos-
pital outpatients setting and 37% were visited in their own home.
Median duration of therapy for those treated was four weeks with
68% attending a single weekly session, a further 22%, who were
predominantly receiving LSVT, had four or more therapy sessions
per week. Most sessions (80%) lasted between 30-60 minutes.
This Cochrane review highlights the fact that there is insufficient
trial evidence to support any form of SLT for speech problems in
Parkinson’s disease. Lee Silverman Voice Therapy (LSVT; Ramig
2001) concentrates solely on volume with participants being en-
couraged to ’think loud’. Johnson 1990 and Robertson 1984 used
a more traditional multi-dimensional approach, both using visual
feedback. They used vocal drills to improve the patients’ overall
speech quality and their perception of their speech.
SPEECH AND LANGUAGE THERAPY TERMINOLOGY
The terminology in this review has been aimed at a general clinical
audience unlike some of the trial reports. It is hoped that this will
improve understanding by non-speech and language therapists. In
an attempt to make reading the original reports easier we have
included a glossary in this review (Table 1: Glossary).
The same outcome measure was often labelled differently in dif-
ferent trials (e.g. volume and sound pressure level), which adds
further to the confusion. It was also difficult for a non-specialist
to determine the value of any given change in the vocal character-
istics measured in these trials. Care should be taken when writing
reports of speech therapy outcomes that an association is made
with the direction and size of change in a given measure and its
impact on the communication ability of the patient. For exam-
ple, pitch range (fundamental frequency variability) is important
because Parkinsonian speech tends to drift towards a monotone
with none of the pitch variations that are important in conveying
the sense of a phrase.
Quality of the evidence
METHODOLOGICAL QUALITY
Methodological quality and standard of reporting was poor. How-
ever, two of the three studies were published before the CON-
SORT guidelines were published (1996).
The trials used insufficient numbers of participants to avoid reach-
ing false negative conclusions and to reduce the possibility of se-
lection bias. Only 29% of the patients enrolled into the trials were
female. This is in contrast to the general population of Parkin-
son’s disease patients where the prevalence of the disease is evenly
divided across the sexes (Tanner 1996). This is a common find-
ing in Parkinson’s disease trials but raises questions as to whether
the results can be generalized across the whole Parkinson’s disease
population and to women in particular.
The method of randomisation was not stated in Johnson 1990.
Alternate allocation was used in Robertson 1984 and Ramig 2001
picked numbers out of a hat, both of which are fallible as these
methods are not truly random and allocation is not concealed.
All three trials failed to clearly define their disease of interest or
state their inclusion and exclusion criteria. It is vital that eligibility
criteria are well defined so that it is understood what sort of a pop-
ulation were treated. For example, it is important that the Parkin-
son’s disease accords with the UK Brain Bank Parkinson’s Disease
criteria (Gibb 1988). This will reduce the likelihood of including
individuals with Parkinson’s plus syndrome which have a signifi-
cantly different clinical course compared to idiopathic Parkinson’s
disease. The eligibility criteria should also define the severity of
Parkinson’s disease and the speech problems in those eligible to
participate, and state clearly any exclusion criteria such as demen-
tia. This would allow an easier assessment of the applicability of
the results in real clinical situations.
It is recognised that inclusion of credible placebo arms in rehabili-
tation therapy trials ismore challenging and expensive than indrug
trials. A control arm receiving ‘no therapy’ leaves both the therapist
and the patient unblinded which could lead to performance bias.
It is important, therefore, to include control groups which account
for time and attention given to active therapy groups. People with
Parkinson’s disease are frequently socially isolated and the atten-
tion paid to them could have a significant impact upon their mood
and perception of their disability. However, it is recognised that a
’placebo’ therapy may be impractical to apply in large multicentre
trials and that an untreated ’best medical practice’ group would
represent a less than adequate comparator. Although the estimate
of the size of improvement due to therapy would be more difficult
to determine because of the placebo effect, which is estimated at
around 16% in Parkinson’s disease (Goetz 2008), this design may
be more reflective of current therapy provision and practice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Improvements in speech impairments were noted in the 41 par-
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ticipants evaluable from these studies, though it cannot be stated
whether or not these changes were of a clinically useful magnitude.
Considering the methodological flaws in many of the studies, the
small number of patients examined, and the possibility of publi-
cation bias, there is insufficient evidence to support or refute the
efficacy of speech and language therapy for speech problems in
Parkinson’s disease.
Implications for research
• To obtain proof of the efficacy of speech and language
therapy for speech disorders in Parkinson’s disease patients large
randomised placebo-controlled trials are required. A rigorous
method of randomisation should be used and the allocation
adequately concealed. Data should be analysed according to
intention-to-treat principles. The trial should be reported
according to the guidelines set out in the CONSORT statement
(CONSORT 1996). This review emphasises many
methodological shortcomings in the three trials of speech and
language therapy versus placebo for speech problems in
Parkinson’s disease. The issues arising from this review have a
significant bearing on the conduct of future speech and language
therapy trials in Parkinson’s disease and other conditions:-
• firm diagnostic criteria should be used (e.g. UK
Parkinson’s Disease Brain Bank Criteria) (Gibb 1988);
• inclusion and exclusion criteria should be clear and
trials should aim to enrol uniform cohorts of Parkinson disease
patients;
• investigators should clarify at what stage of the disease
speech and language therapy is being evaluated;
• trials must have sufficient numbers of participants to
avoid false positive or false negative conclusions;
• ideally trials should include an adequate placebo
control groupalthough it is recognised that an untreated ’best
medical practice’ group may be more practicable;
• trials must include a very clear description of the
therapeutic intervention;
• patients should be followed for at least six months after
treatment to assess any long-term effects of the SLT intervention;
• for some scales, trials should report whether scores on
impairment and disability refer to the ’on’ or ’off ’ phase;
• suitable clinimetrically sound outcome measures
should be chosen so that the efficacy and effectiveness of SLT can
be assessed and an economic analysis performed. Outcomes
which have meaning to Parkinson’s disease patients and carers
should be used wherever possible since they need to know the
value of SLT in practical terms;
• the data must be analysed on an intention-to-treat
basis and the change in an outcome measure must be compared
statistically across the two therapy groups;
• associations between size/direction of changes in
outcome measures and the ability of the patients to
communicate should be made, with intelligibility used as a key
outcome measure to facilitate this.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Johnson 1990
Methods Parallel group design. Randomisation method not stated. Data assumed to be analysed on an
intention-to-treat basis. Treated as outpatients for 10 hours over 4 weeks. Assessed at baseline
and immediately after therapy. The assessor was blinded. British study
Participants 6 patients per arm of study. No drop-outs were stated. Patients mean age 63.5 (treatment),
64.8 (placebo); 5 males and 1 female per group, baseline Hoehn and Yahr and duration of
condition not stated. No inclusion or exclusion criteria stated
Interventions Treatment group: Individual exercises varied to suit patient’s needs, emphasis placed on
prosodic features of pitch and volume with visual feedback used
Placebo group: No treatment described.
Drug therapy was constant for at least 2 months prior to trial
Outcomes Frenchay Dysarthria Assessment
Loudest volume
Volume range
Volume (speech & reading)
Fundamental frequency
Modal pitch (speech & reading)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Specified eligibility criteria Unclear risk Criteria not stated
Randomisation method Unclear risk Randomisation method not stated
Adequate concealment of allocation Unclear risk Randomisation method not stated
Similar at baseline Low risk Groups similar in mean age and male/female
ratio
Withdrawals >10% Low risk No withdrawals
Missing values >10% Low risk No missing data
Cointerventions constant Low risk Stable drug regimen throughout trial period
Credible placebo Unclear risk Effect of time and attention undetermined
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Johnson 1990 (Continued)
Blinded assessors Unclear risk Assessors blinded for Frenchay Dysarthria as-
sessment but not for eight remainingmeasures
Ramig 2001
Methods Parallel group design. Randomised by number pulled out of a hat allocation. Data assumed to
be analysed on an intention-to-treat basis. Treated as outpatients for 16 hours over 4 weeks.
Assessed at baseline and immediately after therapy. Not stated whether assessors were blinded.
American study
Participants 14 patients in treatment group, 15 in placebo. Number of drop-outs not stated. Patients mean
age 67.9 (treatment), 71.2 (placebo); male/female 7/7 (treatment), 7/8 (placebo); Hoehn and
Yahr 3.1 (treatment), 2.2 (placebo); duration of condition/years 8.6 (LSVT), 7.8 (placebo)
. Inclusion criteria: Have adequate hearing for daily communication. No exclusion criteria
stated
Interventions Treatment group: Individual LSVT which targets maximising phonatory efficiency. Placebo
group: Treatment not described. Drug therapy was kept constant
Outcomes Volume for:
sustained vowel ’ah’ phonation,
reading the Rainbow Passage,
speaking freely on self chosen topic,
describing ’The Cookie Theft’ picture.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Specified eligibility criteria Unclear risk Criteria not stated
Randomisation method High risk Randomised by number pulled out of a hat
allocation
Adequate concealment of allocation High risk Randomised by number pulled out of a hat
allocation
Similar at baseline Low risk Groups similar in mean age, male/female ra-
tio, Hoehn & Yahr and duration of condition
Withdrawals >10% Low risk No withdrawals
Missing values >10% Low risk No missing values
Cointerventions constant Low risk Stable drug regimen throughout trial period
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Ramig 2001 (Continued)
Credible placebo Unclear risk Effect of time and attention undetermined
Blinded assessors Unclear risk Not stated whether assessors were blinded
Robertson 1984
Methods Parallel group design. Randomised by alternate allocation. Data analysed on a per protocol
basis. Treated as outpatients for 35-40 hours over 2 weeks. Assessed at baseline, immediately
after therapy and 3 month later. Assessors were not blinded. British study
Participants 12 patients in treatment group, 10 in placebo. 4 drop-outs in placebo group. Patients mean age
58.4 (treatment), 68.1 (placebo); male/female 12/0 (treatment), 5/1 (placebo) - the sex and
age of the drop-outs was not stated. The baseline duration of condition and Hoehn and Yahr
score was not given. Inclusion criteria: Diagnosis of Parkinson’s disease and on well stabilised
drug regime. No exclusion criteria stated
Interventions Treatment group: Group therapy supplemented with individual therapy if needed. Therapy
aimed to improve respiration, voice production, pitch variation, loudness and intelligibility
with video used for feedback. Placebo group: Assessed at same time intervals but no treatment.
Drug therapy was constant
Outcomes Dysarthria profile.
Notes No raw data available.
Risk of bias
Bias Authors’ judgement Support for judgement
Specified eligibility criteria Low risk Inclusion criteria stated
Randomisation method High risk Randomised by alternate allocation
Adequate concealment of allocation High risk Randomised by alternate allocation
Similar at baseline Unclear risk Baseline characteristics for drop-outs not pro-
vided
Withdrawals >10% High risk 4 drop outs from 22 recruited to trial
Missing values >10% High risk Baseline data for 4 drop outs not provided
Cointerventions constant Low risk Stable drug regimen throughout trial period
Credible placebo Unclear risk Effect of time and attention undetermined
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Robertson 1984 (Continued)
Blinded assessors High risk All patients in the treatment group were as-
sessed and re-assessed by therapists not in-
volved in the therapy, while those in the con-
trol group were assessed by the co-authors
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aguiar 2009 Controlled clinical trial compared the effect of a multidisciplinary program, dedicated to non-pharmacological
treatment, with no treatment. No data were available from SLT component
Corte 2009 Trial reported in Portuguese, was carried out with a focus group and is not an RCT, discussions took place about
the importance of alternative practices like playing an instrument on patients with Parkinson’s disease
Cotter 2003 Three armed RCT with two groups receiving different schedules of LSVT and one group receiving no SLT. Trial
registration states the trial was due to run from 2003 to 2005, no data or further information were available and
it could not be confirmed that the trial took place
Evans 2006 Trial of group singing as a form of speech therapy for people with Parkinson’s disease as a method of improving
and maintaining voice dynamics. This study did not include a control arm and hence was not randomised
Katsikitis 1996 RCT examined the effect of orofacial physiotherapy on facial mobility. Although some of the outcome measures
such as ’distance of mouth opening’ are important to intelligible speech, none of the outcome measures quantified
its affect on speech problems. As the aim of the trial was physical this was assessed in the ’Physiotherapy for patients
with Parkinson’s disease’ Cochrane review
Patti 1996 RCT examined the effect of a program of inpatient rehabilitative therapy that included speech and language therapy
if the patient needed it. It was not clear how many of the patients in the study received speech and language
therapy. Also, all of the outcome measures were physiotherapeutic in nature and so this trial was assessed in the
’Physiotherapy for patients with Parkinson’s disease’ Cochrane review
Quedas 2007 Controlled trial based on Lombard’s effect which states that a masking noise will produce a consistent increase in
voice intensity for most normal individuals. People with Parkinson’s disease were evaluated before and after white
masking noise to test for improvement in intensity. The control group in this study consisted of healthy controls
and so the trial was not an RCT
Sapir 2007 Publication describes a sub-group of patients used in the Ramig 2001 study included in this review, however,
additional patients were also randomised for analysis of the vowel articulation outcomes reported in this paper.
The data cannot therefore be analysed as part of the Ramig 2001 trial nor can this be considered a separate trial
due to the overlap of a portion of the patients
Scott 1984 Prosodic abnormalitywas assessed in adultswith Parkinson’s disease before and after a course of intensive domiciliary
prosodic therapy. The control measurements were taken from the same patients over a two week period prior to
the start of therapy so no randomisation of patients was necessary
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(Continued)
Silverman 2006 A sub-group of 3 patients in a trial examining the maximum inspiratory and expiratory mouth pressures of
Parkinson’s disease patients were given expiratory muscle strength training. No control group was used in the
evaluation of this therapy
Wang 2008 Trial evaluated the use of altered auditory feedback to improve intelligibility of speech in patients with Parkinson’s
disease. Treatment pathways were randomised with patients taking part in 5 different testing conditions. No split
data available
Wohlert 2004 Treatment schedules for delivery of LSVT were evaluated to determine the most effective frequency and duration
of sessions. Not all patients who took part in this trial were randomised
Characteristics of ongoing studies [ordered by study ID]
Huber 2011
Trial name or title Use of External Cueing to treat hypophonia in Parkinson’s disease
Methods Assessments made immediately after treatment and 6 months after treatment
Participants Individuals with Parkinson’s disease.
Interventions Treatment group: 8 week training plan with voice-activated appliance which creates babble noise in response
to speech, exploiting Lombard’s effect (background noise naturally and automatically causes louder speech).
Placebo group: Unknown
Outcomes Vocal intensity
Speech intelligibility
Clarity
Communicative competence
Respiratory strength
Respiratory kinematics during speech
Laryngeal aerodynamics
Articulatory acoustics
Starting date 01/04/2011
Contact information jhuber@purdue.edu
Notes American study. Trial registration information. Contacted author for further information but was unsuccessful
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D A T A A N D A N A L Y S E S
Comparison 1. SLT therapy versus no SLT therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 SPL monologue pre/post 2 41 Mean Difference (IV, Fixed, 95% CI) 6.17 [3.57, 8.77]
1.1 LSVT versus no therapy 1 29 Mean Difference (IV, Fixed, 95% CI) 5.40 [2.60, 8.20]
1.2 Therapy with visual
feedback versus no therapy
1 12 Mean Difference (IV, Fixed, 95% CI) 11.0 [3.98, 18.02]
2 SPL reading pre/post 2 41 Mean Difference (IV, Fixed, 95% CI) 7.18 [4.65, 9.71]
2.1 LSVT vs no treatment 1 29 Mean Difference (IV, Fixed, 95% CI) 6.3 [3.50, 9.10]
2.2 Therapy with visual
feedback versus no treatment
1 12 Mean Difference (IV, Fixed, 95% CI) 11.0 [5.15, 16.85]
3 SPL monologue pre/6 month
follow-up
1 29 Mean Difference (IV, Fixed, 95% CI) 3.5 [0.88, 6.12]
4 SPL reading pre/6 month
follow-up
1 29 Mean Difference (IV, Fixed, 95% CI) 4.5 [1.91, 7.09]
5 SPL sustained phonation
pre/post
1 29 Mean Difference (IV, Fixed, 95% CI) 12.10 [8.85, 15.35]
6 SPL sustained phonation pre/6
month follow-up
1 29 Mean Difference (IV, Fixed, 95% CI) 9.40 [6.24, 12.56]
7 SPL describing picture pre/post 1 29 Mean Difference (IV, Fixed, 95% CI) 5.2 [2.02, 8.38]
8 SPL describing picture pre/6
month follow-up
1 29 Mean Difference (IV, Fixed, 95% CI) 4.2 [1.11, 7.29]
9 SPL /i/ 1 29 Mean Difference (IV, Fixed, 95% CI) 8.4 [5.15, 11.65]
10 SPL /u/ 1 29 Mean Difference (IV, Fixed, 95% CI) 5.2 [1.83, 8.57]
11 SPL /a/ 1 29 Mean Difference (IV, Fixed, 95% CI) 7.5 [3.53, 11.47]
12 F2u 1 29 Mean Difference (IV, Fixed, 95% CI) -96.0 [-233.51, 41.
51]
13 F2i/F2u 1 29 Mean Difference (IV, Fixed, 95% CI) 0.18 [-0.02, 0.38]
14 Vowel goodness /i/ 1 29 Mean Difference (IV, Fixed, 95% CI) 15.20 [7.12, 23.28]
15 Vowel goodness /u/ 1 29 Mean Difference (IV, Fixed, 95% CI) 12.20 [5.34, 19.06]
16 Vowel goodness /a/ 1 29 Mean Difference (IV, Fixed, 95% CI) 7.4 [-0.19, 14.99]
Comparison 2. Therapy with visual feedback versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 SPL monologue pre/post 1 12 Mean Difference (IV, Fixed, 95% CI) 11.0 [3.98, 18.02]
2 SPL reading pre/post 1 12 Mean Difference (IV, Fixed, 95% CI) 11.0 [5.15, 16.85]
3 Frenchay dysarthria assessment 1 12 Mean Difference (IV, Fixed, 95% CI) 29.0 [13.66, 44.34]
4 Pitch range pre/post 1 12 Mean Difference (IV, Fixed, 95% CI) 66.1 [-4.44, 136.64]
5 Volume range pre/post 1 12 Mean Difference (IV, Fixed, 95% CI) 23.7 [9.30, 38.10]
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6 Fundamental frequency 1 12 Mean Difference (IV, Fixed, 95% CI) -65.4 [-133.18, 2.
38]
Analysis 1.1. Comparison 1 SLT therapy versus no SLT therapy, Outcome 1 SPL monologue pre/post.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 1 SPL monologue pre/post
Study or subgroup Therapy No Therapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 LSVT versus no therapy
Ramig 2001 14 5.5 (3.8) 15 0.1 (3.9) 86.2 % 5.40 [ 2.60, 8.20 ]
Subtotal (95% CI) 14 15 86.2 % 5.40 [ 2.60, 8.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.78 (P = 0.00016)
2 Therapy with visual feedback versus no therapy
Johnson 1990 6 11.5 (7.8) 6 0.5 (4.01) 13.8 % 11.00 [ 3.98, 18.02 ]
Subtotal (95% CI) 6 6 13.8 % 11.00 [ 3.98, 18.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0021)
Total (95% CI) 20 21 100.0 % 6.17 [ 3.57, 8.77 ]
Heterogeneity: Chi2 = 2.11, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 4.65 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.11, df = 1 (P = 0.15), I2 =53%
-100 -50 0 50 100
Favours No Treatment Favours Treatment
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Analysis 1.2. Comparison 1 SLT therapy versus no SLT therapy, Outcome 2 SPL reading pre/post.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 2 SPL reading pre/post
Study or subgroup Therapy No Therapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 LSVT vs no treatment
Ramig 2001 14 6.6 (3.8) 15 0.3 (3.9) 81.3 % 6.30 [ 3.50, 9.10 ]
Subtotal (95% CI) 14 15 81.3 % 6.30 [ 3.50, 9.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.41 (P = 0.000011)
2 Therapy with visual feedback versus no treatment
Johnson 1990 6 9.5 (5.6) 6 -1.5 (4.7) 18.7 % 11.00 [ 5.15, 16.85 ]
Subtotal (95% CI) 6 6 18.7 % 11.00 [ 5.15, 16.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.69 (P = 0.00023)
Total (95% CI) 20 21 100.0 % 7.18 [ 4.65, 9.71 ]
Heterogeneity: Chi2 = 2.02, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 5.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.02, df = 1 (P = 0.16), I2 =50%
-100 -50 0 50 100
Favours No Treatment Favours Treatment
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Analysis 1.3. Comparison 1 SLT therapy versus no SLT therapy, Outcome 3 SPL monologue pre/6 month
follow-up.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 3 SPL monologue pre/6 month follow-up
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 3.7 (3.6) 15 0.2 (3.6) 100.0 % 3.50 [ 0.88, 6.12 ]
Total (95% CI) 14 15 100.0 % 3.50 [ 0.88, 6.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0089)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 1.4. Comparison 1 SLT therapy versus no SLT therapy, Outcome 4 SPL reading pre/6 month
follow-up.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 4 SPL reading pre/6 month follow-up
Study or subgroup LSVT No Treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 4.8 (3.2) 15 0.3 (3.9) 100.0 % 4.50 [ 1.91, 7.09 ]
Total (95% CI) 14 15 100.0 % 4.50 [ 1.91, 7.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.41 (P = 0.00066)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours No Treatment Favours LSVT
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Analysis 1.5. Comparison 1 SLT therapy versus no SLT therapy, Outcome 5 SPL sustained phonation
pre/post.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 5 SPL sustained phonation pre/post
Study or subgroup LSVT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 13.3 (4.6) 15 1.2 (4.3) 100.0 % 12.10 [ 8.85, 15.35 ]
Total (95% CI) 14 15 100.0 % 12.10 [ 8.85, 15.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.30 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours No Treament Favours LSVT
Analysis 1.6. Comparison 1 SLT therapy versus no SLT therapy, Outcome 6 SPL sustained phonation pre/6
month follow-up.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 6 SPL sustained phonation pre/6 month follow-up
Study or subgroup LSVT No Treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 10.7 (4.56) 15 1.3 (4.1) 100.0 % 9.40 [ 6.24, 12.56 ]
Total (95% CI) 14 15 100.0 % 9.40 [ 6.24, 12.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours No Treatment Favours LSVT
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Analysis 1.7. Comparison 1 SLT therapy versus no SLT therapy, Outcome 7 SPL describing picture pre/post.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 7 SPL describing picture pre/post
Study or subgroup LSVT No Treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 5.5 (4.46) 15 0.3 (4.26) 100.0 % 5.20 [ 2.02, 8.38 ]
Total (95% CI) 14 15 100.0 % 5.20 [ 2.02, 8.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.21 (P = 0.0013)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 1.8. Comparison 1 SLT therapy versus no SLT therapy, Outcome 8 SPL describing picture pre/6
month follow-up.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 8 SPL describing picture pre/6 month follow-up
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 4.5 (4.22) 15 0.3 (4.26) 100.0 % 4.20 [ 1.11, 7.29 ]
Total (95% CI) 14 15 100.0 % 4.20 [ 1.11, 7.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.0077)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 1.9. Comparison 1 SLT therapy versus no SLT therapy, Outcome 9 SPL /i/.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 9 SPL /i/
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 8.3 (4.81) 15 -0.1 (4.07) 100.0 % 8.40 [ 5.15, 11.65 ]
Total (95% CI) 14 15 100.0 % 8.40 [ 5.15, 11.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.06 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 1.10. Comparison 1 SLT therapy versus no SLT therapy, Outcome 10 SPL /u/.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 10 SPL /u/
Study or subgroup LSVT No Treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 5.7 (4.75) 15 0.5 (4.5) 100.0 % 5.20 [ 1.83, 8.57 ]
Total (95% CI) 14 15 100.0 % 5.20 [ 1.83, 8.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 1.11. Comparison 1 SLT therapy versus no SLT therapy, Outcome 11 SPL /a/.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 11 SPL /a/
Study or subgroup LSVT No Treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 8.5 (5.66) 15 1 (5.22) 100.0 % 7.50 [ 3.53, 11.47 ]
Total (95% CI) 14 15 100.0 % 7.50 [ 3.53, 11.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.70 (P = 0.00021)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 1.12. Comparison 1 SLT therapy versus no SLT therapy, Outcome 12 F2u.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 12 F2u
Study or subgroup LSVT No Treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 -76 (182.34) 15 20 (195.49) 100.0 % -96.00 [ -233.51, 41.51 ]
Total (95% CI) 14 15 100.0 % -96.00 [ -233.51, 41.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 1.13. Comparison 1 SLT therapy versus no SLT therapy, Outcome 13 F2i/F2u.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 13 F2i/F2u
Study or subgroup LSVT No Treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 0.16 (0.28) 15 -0.02 (0.27) 100.0 % 0.18 [ -0.02, 0.38 ]
Total (95% CI) 14 15 100.0 % 0.18 [ -0.02, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 1.14. Comparison 1 SLT therapy versus no SLT therapy, Outcome 14 Vowel goodness /i/.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 14 Vowel goodness /i/
Study or subgroup LSVT No Treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 15.5 (12.1) 15 0.3 (9.9) 100.0 % 15.20 [ 7.12, 23.28 ]
Total (95% CI) 14 15 100.0 % 15.20 [ 7.12, 23.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.69 (P = 0.00023)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 1.15. Comparison 1 SLT therapy versus no SLT therapy, Outcome 15 Vowel goodness /u/.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 15 Vowel goodness /u/
Study or subgroup LSVT No Treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 11.4 (10.2) 15 -0.8 (8.5) 100.0 % 12.20 [ 5.34, 19.06 ]
Total (95% CI) 14 15 100.0 % 12.20 [ 5.34, 19.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.49 (P = 0.00049)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 1.16. Comparison 1 SLT therapy versus no SLT therapy, Outcome 16 Vowel goodness /a/.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 1 SLT therapy versus no SLT therapy
Outcome: 16 Vowel goodness /a/
Study or subgroup LSVT No Treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 2001 14 7.9 (11.3) 15 0.5 (9.4) 100.0 % 7.40 [ -0.19, 14.99 ]
Total (95% CI) 14 15 100.0 % 7.40 [ -0.19, 14.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 2.1. Comparison 2 Therapy with visual feedback versus no treatment, Outcome 1 SPL monologue
pre/post.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 2 Therapy with visual feedback versus no treatment
Outcome: 1 SPL monologue pre/post
Study or subgroup Therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Johnson 1990 6 11.5 (7.8) 6 0.5 (4.01) 100.0 % 11.00 [ 3.98, 18.02 ]
Total (95% CI) 6 6 100.0 % 11.00 [ 3.98, 18.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0021)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours No treatment Favours Therapy
Analysis 2.2. Comparison 2 Therapy with visual feedback versus no treatment, Outcome 2 SPL reading
pre/post.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 2 Therapy with visual feedback versus no treatment
Outcome: 2 SPL reading pre/post
Study or subgroup Therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Johnson 1990 6 9.5 (5.6) 6 -1.5 (4.7) 100.0 % 11.00 [ 5.15, 16.85 ]
Total (95% CI) 6 6 100.0 % 11.00 [ 5.15, 16.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.69 (P = 0.00023)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours No Treatment Favours therapy
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Analysis 2.3. Comparison 2 Therapy with visual feedback versus no treatment, Outcome 3 Frenchay
dysarthria assessment.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 2 Therapy with visual feedback versus no treatment
Outcome: 3 Frenchay dysarthria assessment
Study or subgroup Therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Johnson 1990 6 20 (8.05) 6 -9 (17.4) 100.0 % 29.00 [ 13.66, 44.34 ]
Total (95% CI) 6 6 100.0 % 29.00 [ 13.66, 44.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Therapy Favours No Treatment
Analysis 2.4. Comparison 2 Therapy with visual feedback versus no treatment, Outcome 4 Pitch range
pre/post.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 2 Therapy with visual feedback versus no treatment
Outcome: 4 Pitch range pre/post
Study or subgroup Therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Johnson 1990 6 65.6 (74.57) 6 -0.5 (47.03) 100.0 % 66.10 [ -4.44, 136.64 ]
Total (95% CI) 6 6 100.0 % 66.10 [ -4.44, 136.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 2.5. Comparison 2 Therapy with visual feedback versus no treatment, Outcome 5 Volume range
pre/post.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 2 Therapy with visual feedback versus no treatment
Outcome: 5 Volume range pre/post
Study or subgroup Therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Johnson 1990 6 17.2 (10.68) 6 -6.5 (14.49) 100.0 % 23.70 [ 9.30, 38.10 ]
Total (95% CI) 6 6 100.0 % 23.70 [ 9.30, 38.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.23 (P = 0.0013)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 2.6. Comparison 2 Therapy with visual feedback versus no treatment, Outcome 6 Fundamental
frequency.
Review: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease
Comparison: 2 Therapy with visual feedback versus no treatment
Outcome: 6 Fundamental frequency
Study or subgroup Therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Johnson 1990 6 -31.7 (28.4) 6 33.7 (79.8) 100.0 % -65.40 [ -133.18, 2.38 ]
Total (95% CI) 6 6 100.0 % -65.40 [ -133.18, 2.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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A D D I T I O N A L T A B L E S
Table 1. Glossary
TERM DEFINITION
Amplitude The maximum absolute value of a periodically varying quantity.
For a sound wave, the maximum variation in pressure relative
to static conditions (e.g. atmospheric pressure). Small variations
produce weak (or quiet) sounds whilst large variations produce
strong (or loud) sounds. (See loudness below)
Articulation The production of vowels and consonants using both the moving
parts of the mouth (e.g. tongue and lips) and the fixed structure
of the mouth (e.g. hard and soft palate). It does not involve the
voice box
Concealment of allocation The process used to conceal foreknowledge of group assignment,
which should be seen as distinct from blinding. The allocation
process should be impervious to any influence by the person mak-
ing the allocation. Adequate methods of allocation concealment
include: centralised randomisation schemes (telephone randomi-
sation) or sequentially numbered opaque sealed envelopes
Decibel (dB) A unit used to express relative difference in power or intensity,
usually between two acoustic or electric signals, equal to ten times
the common logarithm (i.e. base 10) of the ratio of the two levels.
i.e. 10 log10 (W2/W1) where W1 is the reference power level
and W2 is the quantity being specified in dB relative to W1. It is
commonplace to want to express in decibels, quantities that are
related not to power, but power squared. Examples include sound
pressure and voltage. In such cases the expression for the decibel
level becomes 20 log10 (p2/p1). So that individual quantities can
be specified, default reference values are defined for sound pres-
sure (20x10E-6 pascals), sound power (10E-6 watts) and sound
intensity (10E-12 watts per square meter). For other quantities (e.
g. voltage) a value of unity is often used implicitly. The reference
level for sound pressure (corresponding to 0 dB) was originally set
as an approximation to the threshold of human hearing. A whis-
per has an intensity of ~30 dB, normal speech ~60 dB, a shout
~90 dB and a jet aircraft ~120 dB
Dysarthria Dysarthria is a collective name for a group of speech disorders re-
sulting fromdisturbances inmuscular control of the speechmech-
anism due to damage of the central nervous system. It designates
problems in oral communication due to paralysis, weakness or
incoordination of the speech musculature
Dysprosody Abnormal prosody (see prosody). Loss of the ’melody’ of speech
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Table 1. Glossary (Continued)
Frequency The number of complete cycles of a periodic process occurring
per unit time. For sound waves this is the number of times the
pressure variation cycle occurs in one second. The unit used to
measure frequency is the hertz (Hz) (see below)
Fundamental frequency (F0) The fundamental frequency is the inverse of the period (T0); i.
e. F0 = 1/T0. For complex sounds such as speech, F0 will nor-
mally correspond to the frequency of the lowest harmonic. It is
measured in hertz (see below). The aim of S&LT is to increase
the fundamental frequency of Parkinsonian speech as this leads to
improved intelligibility. See also Pitch (see below)
Fundamental frequency variability The variation in fundamental frequency (see above) of speech.
Measured as the standard deviation of F0 in hertz or semitones
(STSD). The aim of S&LT is to increase F0 variation and thus
decrease the monotonicity of the patient’s speech. See also Pitch
Hertz (Hz) Hertz is the unit of frequency expressed in cycles (sound waves)
per second
Hypophonia A breathy hoarseness to the speech.
Intelligibility Degree of clarity with which utterances are understood by average
listeners. It is influenced by articulation, rate, fluency, vocal quality
and intensity (see below)
Intensity (of sound) The sound power propagating through a unit area of the sound
field in a given direction. For example, the sound intensity of
a point source radiating spherical waves and of a given sound
power, will diminish as the distance from the source is increased,
in proportion to the inverse of the square of this distance (1/
distance squared). It is a vector quantity since it specifies both
a magnitude and direction, therefore direct measurement is not
straightforward. Sound intensity has units of watts per square
metre, but can also be expressed in decibels (see above). Sound
intensity is related to the square of the sound pressure, but the
exact relationship depends on the characteristics of the sound field
Intention-to-treat data analysis Data are analysed according to the randomisation allocation, ir-
respective of protocol violations and withdrawals. Withdrawals,
and therefore missing data points, are usually compensated for
by using the last observation carried forward. Intention-to-treat
analyses are favoured in assessments of effectiveness as they mirror
the non-compliance and treatment changes that are likely to occur
when the intervention is used in practice and because of the risk
of attrition bias when participants are excluded from the analysis
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Table 1. Glossary (Continued)
Loudness Loudness is usually the subjective impression of the level of a
sound. However, in the text of this review we have also mentioned
’objective’ loudness. We define this as being loudness measured
mechanically, see intensity, sound pressure level and decibels. The
subjective loudness of a sound is defined as being relative to the
perceived loudness of a 1000 Hz tone generating a sound pres-
sure level of 70 dB. Loudness is influenced by frequency, level and
waveform shape and is governed by the physiology of the ear. It is
measured in units of phons. Typically, an increase in sound pres-
sure level of 10 dB results in a doubling of loudness. However, at
low levels of loudness, the increase is more like 6 dB for a corre-
sponding perceived change. Loudness is sometimes also referred
to as volume
Monotonicity A lack in variation of both loudness (see above) and pitch (see
below)
Period (T0) The length of each sound wave (cycle) in time is called the period
of a waveform. It is equal to 1/frequency
Per protocol data analysis Data are analysed according to what therapy the patients received,
rather than according to their randomised allocation.Withdrawals
are removed from the analysis. This form of data analysis risks
attrition bias
Phonation The mechanism of producing sounds with the vocal chords.
Pitch The perceptual correlate of frequency (see above). Normally, the
pitch of a complex sound is a function of its fundamental fre-
quency (see above). Equal steps in pitch are roughly equal to log-
arithmic steps in amplitude
Prosody Prosody is defined as that aspect of spoken language which con-
sists in correct placing of pitch and stress on syllables and words. It
is responsible for conveying subtle changes of meaning indepen-
dently of words or grammatical order. In addition to this semantic
role, it makes a major contribution to the emotional content of
speech
Rainbow passage A reading passage that is phonetically balanced and has all the
vowel and consonant sounds present in the English language
Reference values for sound pressure, sound power and sound in-
tensity (P0)
So that individual quantities can be specified in terms of decibels,
default reference values are defined for sound pressure (20x10E-
6 pascals), sound power (10E-6 watts) and sound intensity (10E-
12 watts per square meter). For other quantities (e.g. voltage)
a value of unity is often used implicitly. The reference level for
sound pressure (corresponding to 0 dB) was originally set as an
approximation to the threshold of human hearing. However this
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Table 1. Glossary (Continued)
equivalence has since been questioned
Respiration Breathing.
Sound pressure and Sound pressure level (SPL) Sound pressure is the root mean square (r.m.s) variation in pres-
sure from the static value (e.g. the atmospheric pressure) and is
measured in pascals. The r.m.s variation in pressure from the static
value (e.g. the atmospheric pressure). Sound pressure is measured
in pascals, but can be expressed in decibels (see above), 20 log10
(sound pressure/20x10E-6) whereupon it is referred to as sound
pressure level. Sound pressure is a scalar quantity and is therefore
relatively easy to measure: for example, a microphone responds
to sound pressure. The reference level for sound pressure (corre-
sponding to 0 dB) was originally set as an approximation to the
threshold of human hearing. However, this equivalence has since
been questioned
Volume Equivalent to loudness (see above).
Table 2. Key characteristics of included studies
Study Number of Pa-
tients analysed
Mean Age Mean Hoehn &
Yahr Score
Duration of ther-
apy
Location of ther-
apy sessions
Type of therapy
Johnson 1990 12 64 n/a 10 hours/4 weeks Outpatients Prosodic exercises
with visual feed-
back
Ramig 2001 29 70 2.7 16 hours/4 weeks Outpatients Phonatory effort
Robertson 1984 22 63 n/a 40 hours/2 weeks Outpatients Respiration, loud-
ness, prosody with
visual feedback
Total 63
Table 3. Summary of results - Johnson 1990 & Ramig 2000
Subsection Outcome Study n (SALT/Placebo) Mean difference Pre/
Post (95% CI lower,
upper, P value)
Mean difference Pre/
6 months (95% CI
lower, upper, P value)
General assessments Fren-
chay Dysarthria As-
sessment
Johnson 1990 6/6 29.0 (13.7, 44.3, 0.
0002)
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Table 3. Summary of results - Johnson 1990 & Ramig 2000 (Continued)
Loudness Monologue (dB) Johnson 1990 6/6 11.0 (3.98, 18.02, 0.
002)
Ramig 2001 14/15 5.4 (2.6, 8.2, 0.0002) 3.5 (0.9, 6.1, 0.009)
Describing Picture
(dB)
Ramig 2001 14/15 5.2 (2.0, 8.4, 0.001) 4.2 (1.1, 7.3, 0.008)
Reading (dB) Johnson 1990 6/6 11.0 (5.2, 16.9, 0.
0002)
Ramig 2001 14/15 6.3 (3.5, 9.1, 0.0007 4.5 (1.9, 7.1, 0.0007)
Prolonged ’a’ (dB) Ramig 2001 14/15 12.1 (8.9, 15.4, < 0.
00001)
9.4 (6.2, 12.6, < 0.
00001)
Monotonicity Maximum Pitch
Range (Hz)
Johnson 1990 6/6 66.0 (-4.4, 136.6, 0.
07)
Maximum Volume
Range (dB)
Johnson 1990 6/6 23.7 (9.3, 38.1, 0.001)
Pitch Fundamental Fre-
quency of ’ah’ (Hz)
Johnson 1990 6/6 -65.4 (-133, 2, 0.06)
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Parkinson disease/
13. Parkinson$.tw.
14. 12 or 13
15. exp speech disorders/
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16. exp articulation disorders/
17. dysarthr*.tw.
18. (speech or speak*).tw.
19. intelligib*.tw.
20. dysprod*.tw.
21. hypophoni*.tw.
22. monoton*.tw.
23. phon*.tw.
24. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. exp “rehabilitation of speech and language disorders”/ or exp language therapy/ or exp myofunctional therapy/ or exp speech,
alaryngeal/ or exp speech, esophageal/ or exp speech therapy/ or exp voice training/
26. ((speech or speak* or language or voice or vocal* or articulate* or sing*) adj3 (task* or therap* or treat* or train* or councel*
or intervention* or exercise* or drill)).tw.
27. (Silverman* or LSVT).tw.
28. 25 or 26 or 27
29. 11 and 14 and 24 and 28
30. 11 and 14 and 28
31. 29 or 30
WH A T ’ S N E W
Last assessed as up-to-date: 11 April 2011.
Date Event Description
9 July 2012 New citation required but conclusions have not changed New citation
9 July 2012 New search has been performed Searches have been rerun and new studies were incorpo-
rated
H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 2, 2001
Date Event Description
6 September 2011 New citation required but conclusions have not
changed
Full search and update, new citation added, conclu-
sions unchanged
13 November 2008 Amended Converted to new review format.
9 February 2001 New citation required and conclusions have changed Substantive amendment
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